Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612697 | PMC |
| http://dx.doi.org/10.1136/rmdopen-2014-000011 | DOI Listing |
Publication Analysis
Top Keywords
systemic lupus
8
lupus erythematosus
8
belimumab systemic
4
erythematosus systemic
4
sle
4
erythematosus sle
4
sle challenging
4
challenging autoimmune
4
autoimmune disorders
4
disorders complex
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!